Abstracts tagged "Quality of life and systemic lupus erythematosus (SLE)"

Abstract Number: 388 • 2015 ACR/ARHP Annual Meeting
Pain, Fatigue and the Psychological Impact on Health-Related Quality of Life in Childhood-Onset Lupus
Jordan T. Jones¹, Natoshia Cunningham², Catherine Donnelly³, Susmita Kashikar-Zuck⁴ and Hermine I. Brunner⁵, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Internal Medicine, University of Cincinnati, Cincinnati, OH, ⁴Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology Collaborative Study Group, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Childhood-onset lupus (cSLE) is a chronic autoimmune disease that has negative impact on health-related quality of life (HRQoL), especially when increased disease activity and…
Abstract Number: 1783 • 2015 ACR/ARHP Annual Meeting
Dietary Fish Oil Supplementation Raises Serum Essential Fatty Acid Concentrations in Patients with Systemic Lupus Erythematosus and Correlates with Improvements in Inflammation and Pain
Cristina Arriens¹, Carlos Rodriguez-Navas², David R. Karp¹, Jeffrey McDonald² and Chandra Mohan³, ¹Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ²Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX, ³Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: A comprehensive metabolomic screen comparing sera from patients with systemic lupus erythematosus (SLE) to healthy controls (HC) indicated a relative deficiency in omega-3 fatty…
Abstract Number: 2897 • 2015 ACR/ARHP Annual Meeting
Predictors of Organ Damage Progression and Impact on Health-Related Quality of Life in Systemic Lupus Erythematosus
Alexandra Legge¹, Steve Doucette² and John G. Hanly³, ¹Department of Medicine, Dalhousie University, Halifax, NS, Canada, ²Dalhousie University and Capital Health, Halifax, NS, Canada, ³Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada
Background/Purpose: To describe cumulative organ damage in a longitudinal cohort of SLE patients and to evaluate the impact of key disease-related factors, medical therapies, demographic…
Abstract Number: 3151 • 2015 ACR/ARHP Annual Meeting
Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) Modules for Use in Childhood-Onset Lupus
Jordan T. Jones¹, Janet Wootton², Jun Ying³, Brianna Liberio⁴, Jiha Lee⁵, Adam Carle⁶, Laura Schanberg² and Hermine I. Brunner⁶, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatrics, Duke Medical Center, Durham, NC, ³University of Cincinnati, Cincinnati, OH, ⁴University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Childhood-onset lupus (cSLE) has a substantial negative impact on health-related quality of life (HRQoL). Patient-reported outcomes (PROs) that accurately assess HRQoL and are responsive…
Abstract Number: 1302 • 2014 ACR/ARHP Annual Meeting
The Psychological Impact on Health-Related Quality of Life in Childhood-Onset Lupus
Jordan T. Jones¹, Natoshia Cunningham², Jennifer L. Huggins¹, Susmita Kashikar-Zuck³ and Hermine I. Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Childhood-onset lupus (cSLE) is a chronic autoimmune disease and its effect on health-related quality of life (HRQoL) has not been fully established, but, disease…
Abstract Number: 701 • 2014 ACR/ARHP Annual Meeting
How Important Is Physical Activity for Patients with Systemic Lupus Erythematodes? -Results of Lula-Study
Isabelle Kloubert¹, Gamal Chehab¹, Jutta Richter², Rebecca Fischer-Betz³, Ralph Brinks² and Matthias Schneider¹, ¹Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ³Department of Rheumatology, University of Düsseldorf, Düsseldorf, Germany
Background/Purpose Physical activity (PA) plays a decisive role in primary and secondary prevention in various domains of medicine. Our examination aimed to determine association PA…
Abstract Number: 712 • 2014 ACR/ARHP Annual Meeting
Mapping the Disease-Specific Lupusqol to the SF-6D
Rachel Meacock¹, Mark Harrison², Kathleen McElhone³, Janice Abbott⁴, Sahena Haque⁵, Ian N. Bruce⁶ and Lee- Suan Teh⁷, ¹Centre for Health Economics, The University of Manchester, Manchester, United Kingdom, ²University of British Columbia, Vancouver, BC, Canada, ³Royal Blackburn Hospital, Blackburn, United Kingdom, ⁴University of Central Lancashire, Preston, United Kingdom, ⁵University Hospital of South Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁷Department of Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom
Background/Purpose: The LupusQoL is a measure of health-related quality of life (HRQoL) developed specifically to assess the impact of systemic lupus erythematosus (SLE) and its…
Abstract Number: 711 • 2014 ACR/ARHP Annual Meeting
Is the Disease-Specific Lupusqol Sensitive to Changes of Disease Activity in SLE Patients after Treatment of a Flare?
Kathleen McElhone¹, Jane Burnell², Chris Sutton², Janice Abbott³, Peter Lanyon⁴, Anisur Rahman⁵, Chee-Seng Yee⁶, Mohammed Akil⁷, Yasmeen Ahmad⁸, Ian Bruce⁹, Caroline Gordon¹⁰ and Lee-Suan Teh¹¹, ¹Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom, ²School of Health, University of Central Lancashire, Preston, United Kingdom, ³University of Central Lancashire, Preston, United Kingdom, ⁴Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁵Centre for Rheumatology Research, University College London, London, United Kingdom, ⁶Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom, ⁷Sheffield Center Rheumatic Dis, Sheffield South Yorkshire, United Kingdom, ⁸Department of Rheumatology, Peter Maddison Research Centre, Bangor, United Kingdom, ⁹Kellgren Centre for Rheum, Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ¹⁰Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹¹Department of Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom
Background/Purpose With improving survival in SLE patients, patient-reported health-related quality of life (HRQoL) has become an important outcome. The LupusQoL is a disease-specific patient-derived HRQoL measure…
Abstract Number: 682 • 2014 ACR/ARHP Annual Meeting
Impact of Patient’s Priorities on the Management of Systemic Lupus Erythematosus
Valérie Leclair¹, Holly O. Witteman², Carolyn Neville³, Isabelle Fortin⁴ and Paul R. Fortin⁵, ¹Internal Medicine, Laval University, Department of Internal Medicine, Quebec City, QC, Canada, ²Medicine, Laval University, Family and Emergency Medicine, Quebec City, QC, Canada, ³Epidemiology, Division of Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Canada, Montreal, QC, Canada, ⁴Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁵Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) greatly reduces the quality of life (QoL) and satisfaction with life of affected patients. SLE patients can have numerous unmet…
Abstract Number: 666 • 2014 ACR/ARHP Annual Meeting
Approach to Discriminate Treatment Impact in Both Moderate and Severe SLE: The Atacicept Phase IIb Trial Design
Joan T. Merrill¹, Yong Li², Stephen D. Wax³ and Christopher Tehlirian⁴, ¹Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²R&D Global BioStatistics, EMD Serono, Billerica, MA, ³Global Clinical Development Center - Immunology, EMD Serono Inc, Rockland, MA, ⁴EMD Serono, Rockland, MA
Background/Purpose Increases in background treatment in SLE trials lead to high placebo group responses in patients with moderate but not those with high disease activity…
Abstract Number: 2632 • 2014 ACR/ARHP Annual Meeting
The Cornerstone to Reasonable Allocation of Health Resource: Valuation of Health Utility in Systemic Lupus Erythematosus
Suli Wang and Liangjing Lu, Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: In a time of increasing economic constraints, it is crucial that health systems optimize their resource use to ensure that they generate the maximum…
Abstract Number: 2621 • 2014 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus
Jin-Shei Lai¹, Karen Kaiser¹, Jennifer Beaumont¹, Sally Jensen¹, Amy H Kao², David Van Brunt³ and Shih-Yin Chen², ¹Northwestern University, Chicago, IL, ²Biogen Idec, Cambridge, MA, ³Formerly of Biogen Idec, Cambridge, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-organ chronic autoimmune disease that can negatively affect patients' health-related quality of life (HRQOL). This cross-sectional study collected…
Abstract Number: 2532 • 2013 ACR/ARHP Annual Meeting
Changes In Quality Of Life In The First 5 Years Of Disease In The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Cohort
Murray B. Urowitz¹, Dominique Ibanez¹, Nicole Anderson¹, Dafna D. Gladman¹ and Systemic Lupus SLICC², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²(coordinating centre), Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Medical Outcome Survey Short Form 36 (SF-36) is one of the most widely used tools for measuring patient reported outcomes. In cross-sectional studies,…
Abstract Number: 2536 • 2013 ACR/ARHP Annual Meeting
Lupus Impact Tracker Is Responsive To Changes In Physician Assessed Disease Status By Systemic Lupus Erythematosus Responder Index
Hervé Devilliers^1,2, Mark Kosinski³, Cindy Garris⁴ and Meenakshi Jolly⁵, ¹Clinical investigation and clinical epidemiology center (INSERM CIE01), Dijon, France, ²Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, ³QualityMetric Inc, Lincoln, RI, ⁴US Health Outcomes, GlaxoSmithKline R&D, Research Triangle Park, NC, ⁵Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Lupus Impact Tracker (LIT) is a 10-item patient reported outcome tool to measure the impact of Systemic Lupus Erythematosus (SLE) or its treatment on…
Abstract Number: 2538 • 2013 ACR/ARHP Annual Meeting
Impact Of Omega-3 Fatty Acids On Quality Of Life In Systemic Lupus Erythematosus
Cristina Arriens¹, Chandra Mohan² and David R. Karp³, ¹Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ²University of Houston, Houston, TX, ³Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: A comprehensive metabolomic screen of sera from patients with Systemic Lupus Erythematosus (SLE) has shown that the concentrations of many substrates for energy generation,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].